Doctors have found a better drug than aspirin in preventing heart attacks and strokes, in a discovery that can transform health instructions around the world.
For decades, millions of people were notified of taking aspirin to reduce the risk of cardiovascular event. Daily aspirin daily aspirin makes the blood less sticky and helps prevent heart attacks and strokes.
But now a new study, presented at the largest heart conference in the world, found that Kubiduglu, which is usually thinner, is more effective – without additional danger.
The amazing discovery in the European Society of Heart Diseases in Madrid has been revealed, with data behind the results It was published simultaneously in the Lancet Medical Magazine.
The international paramedic team behind the study, from countries including the United States, the United Kingdom, Australia, Switzerland and Japan, said the results showed that Clubidogger was “superior” over aspirin and should lead to “intense dependence” of drugs in clinical practice around the world.
Their comprehensive analysis of about 29,000 patients suffering from coronary artery disease (CAD) found that Clubidocalus was better than aspirin in preventing serious heart events and stroke, without increasing the risk of severe bleeding.
CAD is the most common form of heart disease and the main cause of death and disability in the world. More than 300 million people live with CAD, including 2.3 million in the United Kingdom.
This happens when the arteries in the heart become narrowed by the accumulation of arteries, which is a fatty substance inside its walls. The pain or discomfort that this stenosis feels angina and if a blockage occurs, it may cause a heart attack.
The results of the old recommendation challenge aspirin as a virtual treatment to prevent serious cardiovascular events in hundreds of millions of CAD patients.
CAD often requires lifelong treatment to prevent heart attacks, strokes, and cardiovascular death. Aspirin is traditionally described indefinitely for patients with condition.
However, evidence that supports the long -term safety and safety was limited. The new analysis of seven clinical trials found that patients who take Clubidogrell suffer from 14 % less risk of cardiovascular or mainly harmful stroke – including heart attack, stroke or cardiovascular death – compared to those who take aspirin.
More importantly, the main bleeding issues in patients were similar between the two drugs, and the fears that Clubidocral may lead to more complications of bleeding.
“This comprehensive synthesis of available evidence indicates that in patients with CAD, a mono -term Clubojerl provides super -term protection against heart attacks and major blood vessels aspirin compared to aspirin, without excessive risk of bleeding.
“The high effectiveness of the Clopidogrel v Aspirin was consistent with multiple major sub -groups, including individuals who have a predictive clinical feature of the weak CloPidogre response, and support the generalization of these results on the wide spectrum of CAD patients.
“These results support the preference of Clubidocalal over aspirin for the chronic anti -platelet treatment for patients with stable CAD. Wide -scale availability, general formulation and the ability to withstand costs from Clubidogrell supports their capabilities for intense dependence in clinical practice.”
The analysis was derived from various patients groups, including those who have undergone procedures such as placing stents or have suffered from acute coronary syndrome, and they examined various sub -groups to ensure that results are widely applied.
It is worth noting that even patients who may respond well well with Clubidocalal as a result of genetic or clinical factors still benefit from its use on aspirin. The results indicate that Clubidogrell should be considered a long -term anti -platelets for patients with CAD.
Since both medicines are widely available, the results have the ability to influence clinical instructions around the world and improve the patient’s results. More research will be needed about the effectiveness of the cost of Clubidocral, as well as broader population studies, to support changes in treatment criteria.
Professor Brian Williams, chief scientific and medical official at the British Heart Foundation, said: “Aspirin is a common prescribed drug to help prevent repetition from heart attacks and strokes.
“More importantly, these benefits come without a greater risk of severe bleeding. These results are likely to affect the medications that doctors prescribe to their patients to reduce the risk of heart problems in the future.”